Literature DB >> 10864983

Variations in genes encoding neutrophil antigens NA1 and NA2.

K Matsuo1, J Procter, D Stroncek.   

Abstract

BACKGROUND: Neutrophil-specific antigens NA1 and NA2 are located on Fcgamma receptor IIIb (FcgammaRIIIb). NA1 and NA2 forms of FcgammaRIIIb differ by four amino acids and the corresponding genes by five nucleotides. Variations in NA gene frequencies are encountered among ethnic groups. Altered forms of the genes are expected among individuals. STUDY DESIGN AND METHODS: RFLPs associated with four recognition sites were used to determine NA genotypes of 232 individuals. When atypical NA genotypes were identified, FcgammaRIIIB and FcgammaRIIIA regions were sequenced.
RESULTS: NA1 FcgammaRIIIB frequency in 100 Japanese (0.66) was greater than that in 53 African Americans (blacks) (0.40; p<0.01) and 79 whites (0.32; p<0.001). Sequencing of atypical FcgammaRIIIB in 16 people confirmed that four blacks had G-->A substitutions at 227; 7 blacks had A-->G substitutions at 277; and 1 Japanese person had C-->G at 141 and G-->T at 227. A at 227 and G at 277 represent expected nts of NA1 FcgammaRIIIB. One black had an NA1 FcgammaRIIIB with a G-->A substitution at 349; A is normally found in NA2 FcgammaRIIIB at 349. Sequencing atypical FcgammaRIIIA in three persons revealed that two blacks had G-->A substitutions at 277 plus C-->A substitutions at 266 and 1 white had previously described T-->G at 230. Two blacks with atypical NA2 FcgammaRIIIB had T-->G FcgammaRIIIA at 230. One black was NA(null).
CONCLUSION: NA2 FcgammaRIIIB is more polymorphic in blacks than in whites or Japanese persons. Chimeric FcgammaRIIIB alleles are most similar to NA2 FcgammaRIIIB. One alternate allele of NA1 (NA1*02) and four alternate alleles of NA2 (NA2*02, NA2*03, NA2*04, and NA2*05) are described.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10864983     DOI: 10.1046/j.1537-2995.2000.40060645.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  7 in total

1.  Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation.

Authors:  Josée Golay; Rut Valgardsdottir; Gerta Musaraj; Damiano Giupponi; Orietta Spinelli; Martino Introna
Journal:  Blood       Date:  2019-01-17       Impact factor: 22.113

Review 2.  Molecular Genetics of the Human Neutrophil Antigens.

Authors:  Brigitte Katharina Flesch; Angelika Reil
Journal:  Transfus Med Hemother       Date:  2018-08-17       Impact factor: 3.747

3.  Genetic analysis of HLA, NA and HPA typing in type 2 diabetes and ASO.

Authors:  S Nomura; A Shouzu; S Omoto; T Matsuzaki; M Yamaoka; M Abe; M Hosokawa; M Nishikawa; T Iwasaka; S Fukuhara
Journal:  Int J Immunogenet       Date:  2006-04       Impact factor: 1.466

Review 4.  Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?

Authors:  Sietse Q Nagelkerke; Taco W Kuijpers
Journal:  Front Immunol       Date:  2015-01-21       Impact factor: 7.561

5.  Characterization of Endogenous Human FcγRIII by Mass Spectrometry Reveals Site, Allele and Sequence Specific Glycosylation.

Authors:  Nathaniel Washburn; Robin Meccariello; Jay Duffner; Kristen Getchell; Kimberly Holte; Thomas Prod'homme; Karunya Srinivasan; Robert Prenovitz; Jonathan Lansing; Ishan Capila; Ganesh Kaundinya; Anthony M Manning; Carlos J Bosques
Journal:  Mol Cell Proteomics       Date:  2018-12-17       Impact factor: 5.911

Review 6.  Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine.

Authors:  Sietse Q Nagelkerke; David E Schmidt; Masja de Haas; Taco W Kuijpers
Journal:  Front Immunol       Date:  2019-10-03       Impact factor: 7.561

7.  Fc γ receptor IIIB (FcγRIIIB) polymorphisms are associated with clinical malaria in Ghanaian children.

Authors:  Bright Adu; Daniel Dodoo; Selorme Adukpo; Paula L Hedley; Fareed K N Arthur; Thomas A Gerds; Severin O Larsen; Michael Christiansen; Michael Theisen
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.